ReviewTherapeutic advances in drug safety2014
Safety of new oral anticoagulant drugs: a perspective.
Review in Therapeutic advances in drug safety, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 62 citations in OpenAlex.
- Bio-inspired one-pot synthesis of luminescent silver nanoparticles and its significant utility as a fluorescence nano sensor for analysis of two adjunctive COVID-19 drugs.BMC chemistry · 2024Article
- Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?The pharmacogenomics journal · 2024Review
- Performance assessment of an electrostatic filter-diverter stent cerebrovascular protection device. Is it possible not to use anticoagulants in atrial fibrilation elderly patients?Frontiers in cardiovascular medicine · 2023Article
- Proximal femur fractures in patients taking anticoagulants.EFORT open reviews · 2020Review
- A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome.Kidney international reports · 2020Article
- Safety of cataract surgery in patients treated with the new oral anticoagulants (NOACs).Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019Article
- Accurate GFR in obesity-protocol for a systematic review.Systematic reviews · 2019Article
- Reversible covalent direct thrombin inhibitors.PloS one · 2018Article
- Review
- Medication Reviews by a Clinical Pharmacist at an Irish University Teaching Hospital.Pharmacy (Basel, Switzerland) · 2017Article
- Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVERJournal of thrombosis and thrombolysis · 2017Article
- Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics.Journal of thrombosis and thrombolysis · 2017Review
- Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report.Thrombosis journal · 2017Article
- First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab.Case reports in cardiology · 2017Article
- Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation.Critical care (London, England) · 2016Review
- Neuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutions.Local and regional anesthesia · 2015Review
- Protein engineering: a new frontier for biological therapeutics.Current drug metabolism · 2014Review
- Perioperative Considerations and Management of Patients Receiving Anticoagulants.Anesthesia, essays and researchesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent development of new oral anticoagulants (NOACs) offers the possibility of efficacy, relative safety and convenience compared with warfarin. This could lead to greater patient compliance, with easier management and improved provision of thromboprophylaxis. Safety whilst using NOACs should be focused on bleeding cases, surgery or on the management of patients receiving anticoagulant therapy with concomitant impairment of renal function, especially since many NOACs are dependent on renal excretion. Thus, if the clearance creatinine indicates severe renal impairment, NOACS will be contraindicated or their dose needs to be changed. In patients who need surgery, there are published protocols of management, depending on the severity of the intervention and renal function. In the case of severe hemorrhage, requiring rapid reversal of the anticoagulant effect and in the absence of specific antidotes, alternatives such as one of the nonspecific haemostatic agents must be considered. Clinical evaluation in bleeding situations and a meticulous risk-benefit appraisal for NOACs is needed, and these procoagulant agents and patients must be monitored closely. This article provides an overview of the pharmacology and potential risks, as well as the efficacy and safety of NOACs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.